Guardant Health (NASDAQ:GH) is up 11% premarket on light volume following its Q3 results released after the close yesterday. Highlights:
Revenue: $60.8M (+180%).
Net loss: ($12.8M) (+48%); loss/share: ($0.14) (+93%).
13,259 (+89%) tests reported to clinical customers, 5,280 (+111%) to biopharma customers.
2019 guidance: Revenue: $202M – 207M from $180M – 190M.
Previously: Guardant Health EPS beats by $0.23, beats on revenue (Nov. 7)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.